Zacks: Analysts Anticipate Mersana Therapeutics Inc (NASDAQ:MRSN) to Announce -$0.37 EPS

Equities analysts forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will report ($0.37) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.39) to ($0.35). Mersana Therapeutics posted earnings per share of ($0.75) during the same quarter last year, which would indicate a positive year over year growth rate of 50.7%. The firm is expected to issue its next earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.78) to ($0.38). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.41) per share, with EPS estimates ranging from ($1.84) to ($1.20). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 63.92%. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $1.08 million.

Several analysts have issued reports on MRSN shares. Cowen reiterated a “buy” rating on shares of Mersana Therapeutics in a research note on Sunday, June 2nd. ValuEngine upgraded shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research cut shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Mersana Therapeutics currently has a consensus rating of “Buy” and an average target price of $11.63.

Several large investors have recently modified their holdings of MRSN. Bank of New York Mellon Corp grew its holdings in shares of Mersana Therapeutics by 19.2% in the fourth quarter. Bank of New York Mellon Corp now owns 39,203 shares of the company’s stock worth $160,000 after purchasing an additional 6,306 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Mersana Therapeutics by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 128,232 shares of the company’s stock worth $523,000 after purchasing an additional 5,798 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Mersana Therapeutics in the fourth quarter worth about $277,000. Bank of America Corp DE lifted its stake in Mersana Therapeutics by 1,409.6% in the fourth quarter. Bank of America Corp DE now owns 31,807 shares of the company’s stock worth $129,000 after acquiring an additional 29,700 shares during the period. Finally, Hikari Power Ltd lifted its stake in Mersana Therapeutics by 5.7% in the first quarter. Hikari Power Ltd now owns 90,246 shares of the company’s stock worth $475,000 after acquiring an additional 4,850 shares during the period. 77.40% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ MRSN traded down $0.08 on Friday, hitting $2.69. The stock had a trading volume of 3,912 shares, compared to its average volume of 145,537. Mersana Therapeutics has a 52-week low of $2.77 and a 52-week high of $15.93. The company has a quick ratio of 6.24, a current ratio of 6.24 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $134.82 million, a P/E ratio of -0.99 and a beta of 1.37. The business has a 50-day moving average of $3.75.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Recommended Story: Why do earnings reports matter?

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.